ALDH3A1 and myelodysplastic syndrome: Additionally, ALDH3A1 CG and GT haplotypes were associated with MDS risk (CG: OR = 1.901, 95%CI 1.181–3.062, p = 0.0104; GT: OR = 2.855, 95%CI 1.253–6.504, p = 0.0200), while CT haplotype carriers have 2.25x lower risk of MDS development (OR = 0.444, 95%CI 0.243–0.812, p = 0.0092).